help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikiforova, M. N.
Right arrow Articles by Nikiforov, Y. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikiforova, M. N.
Right arrow Articles by Nikiforov, Y. E.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*UniGene
*Genetics Home Reference
Medline Plus Health Information
*Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 11 5399-5404
Copyright © 2003 by The Endocrine Society

BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas

Marina N. Nikiforova, Edna T. Kimura, Manoj Gandhi, Paul W. Biddinger, Jeffrey A. Knauf, Fulvio Basolo, Zhaowen Zhu, Riccardo Giannini, Giuliana Salvatore, Alfredo Fusco, Massimo Santoro, James A. Fagin and Yuri E. Nikiforov

Department of Pathology and Laboratory Medicine (M.N.N., M.G., P.W.B., Z.Z., Y.E.N.) and Division of Endocrinology (E.T.K., J.A.K., J.A.F.), University of Cincinnati, Cincinnati, Ohio; Dipartimento di Oncologia (F.B., R.G.), Pisa, Italy; and Dipartimento di Biologia e Patologia Cellulare e Molecolare (G.S., A.F., M.S.), University ‘Federico II’ c/o Istituto di Endocrinologia ed Oncologia Sperimentale, Consiglio Nazionale delle Ricerche, Naples, Italy

Address all correspondence and requests for reprints to: Dr. Yuri Nikiforov, Department of Pathology, University of Cincinnati, 231 Albert Sabin Way, P.O. Box 670529, Cincinnati, Ohio 45267-0529. E-mail: yuri.nikiforov{at}uc.edu.

Activating point mutations of the BRAF gene have been recently reported in papillary thyroid carcinomas. In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell lines and detected BRAF mutations in 45 (38%) papillary carcinomas, two (13%) poorly-differentiated carcinomas, three (10%) anaplastic carcinomas, and five (83%) thyroid anaplastic carcinoma cell lines but not in follicular, Hürthle cell, and medullary carcinomas, follicular and Hürthle cell adenomas, or benign hyperplastic nodules. All mutations involved a T->A transversion at nucleotide 1796. In papillary carcinomas, BRAF mutations were associated with older age, classic papillary carcinoma or tall cell variant histology, extrathyroidal extension, and more frequent presentation at stages III and IV. All BRAF-positive poorly differentiated and anaplastic carcinomas contained areas of preexisting papillary carcinoma, and mutation was present in both the well-differentiated and dedifferentiated components. These data indicate that BRAF mutations are restricted to papillary carcinomas and poorly differentiated and anaplastic carcinomas arising from papillary carcinomas. They are associated with distinct phenotypical and biological properties of papillary carcinomas and may participate in progression to poorly differentiated and anaplastic carcinomas.

This work was supported by the American Cancer Society Grant RSG-03-027-01-CCE (to Y.E.N.), National Institutes of Health (NIH) Grant CA50706 (to J.A.F.), and funds from the Italian Association for Cancer Research. Tissue samples were collected, in part, using a support by grant from the NIH (PHS M01 RR08084 to the Children’s Hospital-University of Cincinnati General Clinical Research Center Tissue Procurement Facility) and through the Cooperative Human Tissue Network, which is funded by the National Cancer Institute.

Abbreviations: FMCA, Fluorescence melting curve analysis; SSCP, single-strand conformational polymorphism; V599E, valine-to-glutamate substitution at residue 599; WT, wild-type.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke
Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. Romei, R. Ciampi, P. Faviana, L. Agate, E. Molinaro, V. Bottici, F. Basolo, P. Miccoli, F. Pacini, A. Pinchera, et al.
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer
Endocr. Relat. Cancer, June 1, 2008; 15(2): 511 - 520.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Leboeuf, J. E. Baumgartner, M. Benezra, R. Malaguarnera, D. Solit, C. A. Pratilas, N. Rosen, J. A. Knauf, and J. A. Fagin
BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2194 - 2201.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Geli, N. Kiss, M. Karimi, J.-J. Lee, M. Backdahl, T. J. Ekstrom, and C. Larsson
Global and Regional CpG Methylation in Pheochromocytomas and Abdominal Paragangliomas: Association to Malignant Behavior
Clin. Cancer Res., May 1, 2008; 14(9): 2551 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. Sala, L. Mologni, S. Truffa, C. Gaetano, G. E. Bollag, and C. Gambacorti-Passerini
BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
Mol. Cancer Res., May 1, 2008; 6(5): 751 - 759.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Y. Wang, M. Ji, W. Wang, Z. Miao, P. Hou, X. Chen, F. Xu, G. Zhu, X. Sun, Y. Li, et al.
Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer
Endocr. Relat. Cancer, March 1, 2008; 15(1): 183 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
F Frasca, C Nucera, G Pellegriti, P Gangemi, M Attard, M Stella, M Loda, V Vella, C Giordano, F Trimarchi, et al.
BRAF(V600E) mutation and the biology of papillary thyroid cancer
Endocr. Relat. Cancer, March 1, 2008; 15(1): 191 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
B. M Cavaco, P. F Batista, C. Martins, A. Banito, F. do Rosario, E. Limbert, L. G Sobrinho, and V. Leite
Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations
Endocr. Relat. Cancer, March 1, 2008; 15(1): 207 - 215.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Abubaker, Z. Jehan, P. Bavi, M. Sultana, S. Al-Harbi, M. Ibrahim, A. Al-Nuaim, M. Ahmed, T. Amin, M. Al-Fehaily, et al.
Clinicopathological Analysis of Papillary Thyroid Cancer with PIK3CA Alterations in a Middle Eastern Population
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 611 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
S.-H. Ahn, Y. Henderson, Y. Kang, C. Chattopadhyay, P. Holton, M. Wang, K. Briggs, and G. L. Clayman
An Orthotopic Model of Papillary Thyroid Carcinoma in Athymic Nude Mice
Arch Otolaryngol Head Neck Surg, February 1, 2008; 134(2): 190 - 197.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A Salajegheh, E B Petcu, R A Smith, and A K-Y Lam
Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists
Postgrad. Med. J., February 1, 2008; 84(988): 78 - 82.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Santarpia, A. K. El-Naggar, G. J. Cote, J. N. Myers, and S. I. Sherman
Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 278 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G. Riesco-Eizaguirre and P. Santisteban
New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy
Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Xing
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
Endocr. Rev., December 1, 2007; 28(7): 742 - 762.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccoli, et al.
Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4085 - 4090.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L. R Rowe, B. G Bentz, and J. S Bentz
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis
J. Clin. Pathol., November 1, 2007; 60(11): 1211 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. C. Ridgway, Y. Tomer, and S. M. McLachlan
Update in Thyroidology
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3755 - 3761.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H.-M. Wang, Y.-W. Huang, J.-S. Huang, C.-H. Wang, V. C. Kok, C.-M. Hung, H.-M. Chen, and C.-Y. Tzen
Anaplastic Carcinoma of the Thyroid Arising More Often from Follicular Carcinoma than Papillary Carcinoma
Ann. Surg. Oncol., October 1, 2007; 14(10): 3011 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Cerutti, G. Oler, P. Michaluart Jr., R. Delcelo, R. M. Beaty, J. Shoemaker, and G. J. Riggins
Molecular Profiling of Matched Samples Identifies Biomarkers of Papillary Thyroid Carcinoma Lymph Node Metastasis
Cancer Res., August 15, 2007; 67(16): 7885 - 7892.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Akeno-Stuart, M. Croyle, J. A. Knauf, R. Malaguarnera, D. Vitagliano, M. Santoro, C. Stephan, K. Grosios, M. Wartmann, R. Cozens, et al.
The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells
Cancer Res., July 15, 2007; 67(14): 6956 - 6964.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Liu, Z. Liu, S. Condouris, and M. Xing
BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2264 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Eszlinger, K. Krohn, A. Kukulska, B. Jarzab, and R. Paschke
Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors
Endocr. Rev., May 1, 2007; 28(3): 322 - 338.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani
Toward a Molecular Classification of Melanoma
J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
R. Flavin, P. Smyth, P. Crotty, S. Finn, S. Cahill, K. Denning, Jinghuan Li, E. O'Regan, J. O'Leary, and O. Sheils
BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii
International Journal of Surgical Pathology, April 1, 2007; 15(2): 116 - 120.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
R. Ciampi and Y. E. Nikiforov
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Endocrinology, March 1, 2007; 148(3): 936 - 941.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Xing
Gene Methylation in Thyroid Tumorigenesis
Endocrinology, March 1, 2007; 148(3): 948 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. S. Mitsiades, J. Negri, C. McMullan, D. W. McMillin, E. Sozopoulos, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, V. Poulaki, D. Batt, et al.
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
Mol. Cancer Ther., March 1, 2007; 6(3): 1070 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Vasko, A. V. Espinosa, W. Scouten, H. He, H. Auer, S. Liyanarachchi, A. Larin, V. Savchenko, G. L. Francis, A. de la Chapelle, et al.
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion
PNAS, February 20, 2007; 104(8): 2803 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Liu, S. Hu, P. Hou, D. Jiang, S. Condouris, and M. Xing
Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant
Clin. Cancer Res., February 15, 2007; 13(4): 1341 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
I. Palona, H. Namba, N. Mitsutake, D. Starenki, A. Podtcheko, I. Sedliarou, A. Ohtsuru, V. Saenko, Y. Nagayama, K. Umezawa, et al.
BRAFV600E Promotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor {kappa}B Activation
Endocrinology, December 1, 2006; 147(12): 5699 - 5707.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
E. A. Mittendorf, A. Khiyami, and C. R. McHenry
When Fine-Needle Aspiration Biopsy Cannot Exclude Papillary Thyroid Cancer: A Therapeutic Dilemma
Arch Surg, October 1, 2006; 141(10): 961 - 966.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. S. Jo, S. Li, J. H. Song, K. H. Kwon, J. C. Lee, S. Y. Rha, H. J. Lee, J. Y. Sul, G. R. Kweon, H.-k. Ro, et al.
Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in Papillary Thyroid Cancer
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3667 - 3670.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Z. Zhu, R. Ciampi, M. N. Nikiforova, M. Gandhi, and Y. E. Nikiforov
Prevalence of RET/PTC Rearrangements in Thyroid Papillary Carcinomas: Effects of the Detection Methods and Genetic Heterogeneity
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3603 - 3610.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Mesa Jr., M. Mirza, N. Mitsutake, M. Sartor, M. Medvedovic, C. Tomlinson, J. A Knauf, G. F. Weber, and J. A. Fagin
Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling.
Cancer Res., July 1, 2006; 66(13): 6521 - 6529.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M Niedziela
Pathogenesis, diagnosis and management of thyroid nodules in children.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 427 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L Fugazzola, E Puxeddu, N Avenia, C Romei, V Cirello, A Cavaliere, P Faviana, D Mannavola, S Moretti, S Rossi, et al.
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 455 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Chiloeches and R. Marais
Is BRAF the Achilles' Heel of Thyroid Cancer?
Clin. Cancer Res., March 15, 2006; 12(6): 1661 - 1664.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Ouyang, J. A. Knauf, E. P. Smith, L. Zhang, T. Ramsey, N. Yusuff, D. Batt, and J. A. Fagin
Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo.
Clin. Cancer Res., March 15, 2006; 12(6): 1785 - 1793.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G Riesco-Eizaguirre, P Gutierrez-Martinez, M A Garcia-Cabezas, M Nistal, and P Santisteban
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 257 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Salvatore, V. De Falco, P. Salerno, T. C. Nappi, S. Pepe, G. Troncone, F. Carlomagno, R. M. Melillo, S. M. Wilhelm, and M. Santoro
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Clin. Cancer Res., March 1, 2006; 12(5): 1623 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. R. Sapio, D. Posca, G. Troncone, G. Pettinato, L. Palombini, G. Rossi, G. Fenzi, and M. Vitale
Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA)
Eur. J. Endocrinol., February 1, 2006; 154(2): 341 - 348.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Castro, A. P. Rebocho, R. J. Soares, J. Magalhaes, L. Roque, V. Trovisco, I. Vieira de Castro, M. Cardoso-de-Oliveira, E. Fonseca, P. Soares, et al.
PAX8-PPAR{gamma} Rearrangement Is Frequently Detected in the Follicular Variant of Papillary Thyroid Carcinoma
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 213 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. He, K. Jazdzewski, W. Li, S. Liyanarachchi, R. Nagy, S. Volinia, G. A. Calin, C.-g. Liu, K. Franssila, S. Suster, et al.
The role of microRNA genes in papillary thyroid carcinoma
PNAS, December 27, 2005; 102(52): 19075 - 19080.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Xing, W. H. Westra, R. P. Tufano, Y. Cohen, E. Rosenbaum, K. J. Rhoden, K. A. Carson, V. Vasko, A. Larin, G. Tallini, et al.
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6373 - 6379.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Beeram, A. Patnaik, and E. K. Rowinsky
Raf: A Strategic Target for Therapeutic Development Against Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Guarino, P. Faviana, G. Salvatore, M. D. Castellone, A. M. Cirafici, V. De Falco, A. Celetti, R. Giannini, F. Basolo, R. M. Melillo, et al.
Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5270 - 5278.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Vasko, S. Hu, G. Wu, J. C. Xing, A. Larin, V. Savchenko, B. Trink, and M. Xing
High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5265 - 5269.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. J. Marx and W. F. Simonds
Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes
Endocr. Rev., August 1, 2005; 26(5): 615 - 661.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Guida, G. Salvatore, P. Faviana, R. Giannini, G. Garcia-Rostan, L. Provitera, F. Basolo, A. Fusco, F. Carlomagno, and M. Santoro
Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4703 - 4709.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. M. Shattuck, W. H. Westra, P. W. Ladenson, and A. Arnold
Independent Clonal Origins of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma
N. Engl. J. Med., June 9, 2005; 352(23): 2406 - 2412.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M Xing
BRAF mutation in thyroid cancer
Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Knauf, X. Ma, E. P. Smith, L. Zhang, N. Mitsutake, X.-H. Liao, S. Refetoff, Y. E. Nikiforov, and J. A. Fagin
Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation
Cancer Res., May 15, 2005; 65(10): 4238 - 4245.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Porra, C. Ferraro-Peyret, C. Durand, S. Selmi-Ruby, H. Giroud, N. Berger-Dutrieux, M. Decaussin, J.-L. Peix, C. Bournaud, J. Orgiazzi, et al.
Silencing of the Tumor Suppressor Gene SLC5A8 Is Associated with BRAF Mutations in Classical Papillary Thyroid Carcinomas
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3028 - 3035.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Mitsutake, J. A. Knauf, S. Mitsutake, C. Mesa Jr., L. Zhang, and J. A. Fagin
Conditional BRAFV600E Expression Induces DNA Synthesis, Apoptosis, Dedifferentiation, and Chromosomal Instability in Thyroid PCCL3 Cells
Cancer Res., March 15, 2005; 65(6): 2465 - 2473.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. E. Nikiforov
Anaplastic Carcinoma of the Thyroid--Will Aurora B Light a Path for Treatment?
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1243 - 1245.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Sorrentino, S. Libertini, P. L. Pallante, G. Troncone, L. Palombini, V. Bavetsias, D. Spalletti-Cernia, P. Laccetti, S. Linardopoulos, P. Chieffi, et al.
Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phenotype and Is Required for Thyroid Carcinoma Cell Proliferation
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 928 - 935.
[Abstract] [Full Text] [PDF]